Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia.
de Porto, Alexander P; Liu, Zhe; de Beer, Regina; Florquin, Sandrine; de Boer, Onno J; Hendriks, Rudi W; van der Poll, Tom; de Vos, Alex F.
; 25(1): 3, 2019 01 15.
Artigo em Inglês | MEDLINE | ID: mdl-30646846
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia.
PcpA Promotes Higher Levels of Infection and Modulates Recruitment of Myeloid-Derived Suppressor Cells during Pneumococcal Pneumonia.
Neumonía neumocócica bacteriémica en adultos en hospital regional de Chile.
Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study.
Arginase 1 activity worsens lung-protective immunity against Streptococcus pneumoniae infection.
Limited Efficacy of Antibacterial Vaccination Against Secondary Serotype 3 Pneumococcal Pneumonia Following Influenza Infection.
Inhibition of Phosphodiesterase-4 during Pneumococcal Pneumonia Reduces Inflammation and Lung Injury in Mice.
Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia.
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.